Based on the Orgenesis Inc stock forecast from 0 analysts, the average analyst target price for Orgenesis Inc is not available over the next 12 months. Orgenesis Inc’s average analyst rating is not available. Stock Target Advisor’s own stock analysis of Orgenesis Inc is Very Bearish, which is based on 0 positive signals and 7 negative signals. At the last closing, Orgenesis Inc’s stock price was USD 2.48. Orgenesis Inc’s stock price has changed by -0.80% over the past week, -11.51% over the past month and -50.49% over the last year.
No recent analyst target price found for Orgenesis Inc
No recent average analyst rating found for Orgenesis Inc
Company Overview Orgenesis Inc
Orgenesis Inc., a biotech company, focuses on cell and gene therapies worldwide. It operates through two segments, Octomera and Therapies. The company develops a Point of Care (POCare) platform that includes a pipeline of licensed cell based POCare therapies that are processed and produced under closed and automated POCare technology systems across a collaborative POCare network consisting of research institutes and hospitals. Its therapies include autologous; cell-based immunotherapies; and therapeutics for metabolic diseases, anti-viral diseases, and tissue regeneration. The company also provides development services, including regulatory services, pre-clinical studies, intellectual property services, and GMP process translation, as well as support services; hospital services; cell process development services; and distributed cell processing services. The company was formerly known as Business Outsourcing Service, Inc. and changed its name to Orgenesis Inc. in August 2011. Orgenesis Inc. was incorporated in 2008 and is headquartered in Germantown, Maryland. Read Less
Orgenesis Inc., a biotech company, focuses on cell and gene therapies worldwide. It operates through two segments, Octomera and Therapies. The company develops a Point of Care (POCare) platform that includes a pipeline of licensed cell based POCare therapies that are processed an...Read More
Frequently Asked Questions About Orgenesis Inc (ORGS) Stock
Stock Target Advisor's fundamental analysis for Orgenesis Inc's stock is Very Bearish.
Unfortunately we do not have enough data on ORGS's stock to indicate if its a good dividend stock.
Unfortunately we do not have enough data on ORGS's stock to indicate what its average analyst target is.
ORGS stock's Price/Earning ratio is 16.26.
Our analysis grades ORGS stock's Price / Earning ratio at F. This means that ORGS stock's Price/Earning ratio is above 58.00000000000001% of the stocks in the Biotechnology sector in the OTC exchange.
Based on this ORGS may be a overvalued for its sector.
The last closing price of ORGS's stock was USD 2.48.
The most recent market capitalization for ORGS is USD 0.01B.
Unfortunately we do not have enough analyst data on ORGS's stock to indicate whether its price will go up or not.
We can't find any ETFs which contains Orgenesis Inc's stock.
As per our most recent records Orgenesis Inc has 146 Employees.
Orgenesis Inc's registered address is 20271 Goldenrod Lane, Germantown, MD, United States, 20876.
You can get more information about it from Orgenesis Inc's website at https://orgenesis.com.
Heading 1
Heading 2
Heading 3
Heading 4
Heading 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Stock Target Advisor's Analysis
This is a composite scorecard based on the application of evaluation criteria deemed most important by analysts. This is not a buy or sell recommendation.
What to like
There is nothing we particularly like
What not to like
Overpriced compared to earnings
The stock is trading high compared to its peers on a price to earning basis and is above the sector median.
Below median dividend returns
The company’s average income yield over the past 5 years has been low compared to its peers. However, it is not a problem if you are not looking for income.
Poor risk adjusted returns
This company is delivering below median risk adjusted returns in its peers. Even if it is outperforming on returns , the returns are unpredictable. Proceed with caution.
Negative cashflow
The company had negative total cash flow in the most recent four quarters.
Negative free cash flow
The company had negative total free cash flow in the most recent four quarters.
Low Revenue Growth
This stock has shown below median revenue growth in the previous 5 years compared to its sector
Low Earnings Growth
This stock has shown below median earnings growth in the previous 5 years compared to its sector
Frequently Asked Questions About Orgenesis Inc (ORGS) Stock
Stock Target Advisor's fundamental analysis for Orgenesis Inc's stock is Very Bearish.
Unfortunately we do not have enough data on ORGS's stock to indicate if its a good dividend stock.
Unfortunately we do not have enough data on ORGS's stock to indicate what its average analyst target is.
ORGS stock's Price/Earning ratio is 16.26.
Our analysis grades ORGS stock's Price / Earning ratio at F. This means that ORGS stock's Price/Earning ratio is above 58.00000000000001% of the stocks in the Biotechnology sector in the OTC exchange.
Based on this ORGS may be a overvalued for its sector.
The last closing price of ORGS's stock was USD 2.48.
The most recent market capitalization for ORGS is USD 0.01B.
Unfortunately we do not have enough analyst data on ORGS's stock to indicate whether its price will go up or not.
We can't find any ETFs which contains Orgenesis Inc's stock.
As per our most recent records Orgenesis Inc has 146 Employees.
Orgenesis Inc's registered address is 20271 Goldenrod Lane, Germantown, MD, United States, 20876.
You can get more information about it from Orgenesis Inc's website at https://orgenesis.com.
Add to Watchlists
loading..
Thank you for Sharing your Stock Targets for ORGS !
Loading...
Please login to proceed
Sorry - extended search is only available for registered users.
